ACHE and Alzheimer disease: Indeed, in a recentbibliometric analysis we found that (i) roughly three-quarters ofthe multitarget anti-AD compounds developed so far hit AChE as oneof the targets (Figure 14) and (ii) linked hybrids are the preferred design strategy,accounting for 40% of all multitarget anti-AD compounds (Figure 15).52 This proportion is likely higher in the specific case ofAChE-inhibitor-based multitarget compounds since linked hybrids tendto be rather large molecules that are particularly suitable to spanthe long cavities with multiple binding sites of proteins.